Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-...

Related Keywords

United Kingdom ,United States ,Colorado ,Chicago ,Illinois ,Boston ,Massachusetts ,David Connolly ,Megan Kelsey ,Adam Daley ,European Commission ,Nasdaq ,Berry Company Public Relations ,Pediatric Endocrine Society ,Rhythm Pharmaceuticals ,Corporate Communications ,United Kingdom Medicines Healthcare Products Regulatory Agency ,Rhythm Pharmaceuticals Inc ,Drug Administration ,Exchange Commission ,European Union ,Annual Meeting ,New Drug Application ,Weight Reduction ,Pediatric Age Groups With Rare ,Related Obesity Treated With ,Healthcare Products Regulatory Agency ,Pre Existing Nevi ,Sexual Arousal ,Suicidal Ideation ,Serious Adverse Reactions Due ,Benzyl Alcohol Preservative ,Low Birth Weight Infants ,Product Characteristics ,Prescribing Information ,Important Safety ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Company Public Relations ,Markets ,